Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia

Journal of Infection

Volumn 65, Issue 6, 2012, Pages 505-512

  Park, Hyun Jung ^a   Kim, Sung Han ^a   Kim, Min Ju ^a   Lee, Yu Mi ^a   Park, So Youn ^a   Moon, Song Mi ^a   Park, Ki Ho ^a   Chong, Yong Pil ^a   Lee, Sang Oh ^a   Choi, Sang Ho ^a   Woo, Jun Hee ^a   Kim, Yang Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Bacteremia; Glycopeptide; Linezolid; S. aureus

Indexed keywords

CARBAPENEM; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; SALVAGE THERAPY; TREATMENT DURATION; TREND STUDY;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; GLYCOPEPTIDES; HUMANS; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; OXAZOLIDINONES; RISK FACTORS; SALVAGE THERAPY; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84869080926     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.08.007     Document Type: Article

References (30)

1. Boucher H.W., Corey G.R. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(Suppl. 5):S344-S349.
2. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
3. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
4. Kim S.H., Park W.B., Lee K.D., Kang C.I., Kim H.B., Oh M.D., et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003, 37:794-799.
5. Lin S.H., Liao W.H., Lai C.C., Liao C.H., Tan C.K., Wang C.Y., et al. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob Chemother 2010, 65:1792-1798.
6. Jang H.C., Kim S.H., Kim K.H., Kim C.J., Lee S., Song K.H., et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009, 49:395-401.
7. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
8. Moise P.A., Forrest A., Birmingham M.C., Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002, 50:1017-1026.
9. Braitman L.E., Rosenbaum P.R. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002, 137:693-695.
10. Durack D.T. Evaluating and optimizing outcomes of surgery for endocarditis. JAMA 2003, 290:3250-3251.
11. Friedman N.D., Kaye K.S., Stout J.E., McGarry S.A., Trivette S.L., Briggs J.P., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
12. Libman H., Arbeit R.D. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984, 144:541-545.
13. Jenkins T.C., Price C.S., Sabel A.L., Mehler P.S., Burman W.J. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:1000-1008.
14. Li J.S., Sexton D.J., Mick N., Nettles R., Fowler V.G., Ryan T., et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000, 30:633-638.
15. Kim S.H., Park W.B., Lee K.D., Kang C.I., Bang J.W., Kim H.B., et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004, 54:489-497.
16. Fowler V.G., Sakoulas G., McIntyre L.M., Meka V.G., Arbeit R.D., Cabell C.H., et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004, 190:1140-1149.
17. Khatib R., Johnson L.B., Fakih M.G., Riederer K., Khosrovaneh A., Shamse Tabriz M., et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006, 38:7-14.
18. Hageman J.C., Liedtke L.A., Sunenshine R.H., Strausbaugh L.J., McDonald L.C., Tenover F.C. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006, 43:e42-e45.
19. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
20. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
21. Kullar R., Davis S.L., Levine D.P., Rybak M.J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52:975-981.
22. Shorr A.F., Kunkel M.J., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005, 56:923-929.
23. Ruiz M.E., Guerrero I.C., Tuazon C.U. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002, 35:1018-1020.
24. Wilcox M.H., Tack K.J., Bouza E., Herr D.L., Ruf B.R., Ijzerman M.M., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212.
25. Jacqueline C., Caillon J., Grossi O., Le Mabecque V., Miegeville A.F., Bugnon D., et al. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:2547-2549.
26. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
27. Moore C.L., Osaki-Kiyan P., Haque N.Z., Perri M.B., Donabedian S., Zervos M.J. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2011.
28. Cunha B.A., Pherez F.M. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur J Clin Microbiol Infect Dis 2009, 28:831-833.
29. Kim S.H., Park W.B., Lee C.S., Kang C.I., Bang J.W., Kim H.B., et al. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect 2006, 12:13-21.
30. Kim S.H., Hong S.B., Yun S.C., Choi W.I., Ahn J.J., Lee Y.J., et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011, 183:1207-1214.